MASP2: A Potential Drug Target and Biomarker for Serine Protease-Driven Diseases

Target Name: MASP2

NCBI ID: G10747

MASP2

MASP2: A Potential Drug Target and Biomarker for Serine Protease-Driven Diseases

MASP2 (MBL-associated serine protease 2) is a highly conserved protein that is expressed in various cell types of the human body. It is a member of the serine protease family 11 and is involved in the regulation of cellular signaling pathways, cell adhesion, and tissue homeostasis. MASP2 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, MASP2 has emerged as a promising drug target and biomarker for a variety of diseases.

MASP2 Structure and Function

MASP2 is a 21-kDa protein that is expressed in a variety of tissues, including muscle, liver, kidney, and heart. It is highly conserved, with a calculated pI of 6.4 and a predicted hydrophobicity of 0.42. MASP2 is localized to the endoplasmic reticulum (ER) and can be retrievied from the ER by various means, including lipid-based liposomal delivery and transfection. Once MASP2 is in the cytosol, it can be targeted to specific cellular compartments, including the endoplasmic reticulum, the cytosol, and the cell surface.

MASP2 is involved in a number of cellular signaling pathways, including cell adhesion, migration, and the regulation of T cell responses. It has been shown to play a role in the regulation of the FGF signaling pathway, which is involved in the development and maintenance of tissues and organs. MASP2 has also been shown to be involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and immune responses.

In addition to its role in cellular signaling pathways, MASP2 has also been implicated in the development and progression of a number of diseases. For example, MASP2 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been implicated in the development of cancer, including colon cancer. In addition, MASP2 has been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

Drug Targeting MASP2

MASP2 has emerged as a promising drug target due to its involvement in a number of diseases. One potential approach to targeting MASP2 is to use small molecules that can inhibit its activity. This can be done by modifying the activity of MASP2 or by inhibiting the activity of enzymes that are involved in its regulation.

One class of small molecules that have been shown to inhibit MASP2 activity is the so-called \"ASP-in-peptide\" drugs. These drugs are designed to bind to specific serine proteases, including MASP2, and inhibit their activity. Examples of ASP-in-peptide drugs include AE-ASP, which is currently in clinical trials for the treatment of Alzheimer's disease, and ASP-220, which is being developed for the treatment of cancer.

Another approach to targeting MASP2 is to use antibodies that can specifically bind to MASP2 and inhibit its activity. This can be done by using antibodies that are designed to bind to MASP2 and can be used in a variety of settings, including cancer immunotherapy and neurodegenerative diseases. Examples of antibodies that have been shown to be effective in targeting MASP2 include monoclonal antibodies, such as AE1234 and ASP-14, and bispecific antibodies, such as API-123 and ASP-36.

Biomarker Development

MASP2 has also been used as a biomarker for a number of diseases. For example, MASP2 has been shown to be involved in the regulation of

Protein Name: MBL Associated Serine Protease 2

Functions: Serum protease that plays an important role in the activation of the complement system via mannose-binding lectin. After activation by auto-catalytic cleavage it cleaves C2 and C4, leading to their activation and to the formation of C3 convertase

The "MASP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MASP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets